louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02000570: Dynamic Preload Indicators in Sitting Position
Official title: Abilities of Dynamic Preload Dependence Indicators to Predict Fluid Responsiveness During Neurosurgery in Sitting Position
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neurosurgery in Sitting Position
Keywords: sitting position
PPV
SVV
PVI
fluid challenge
preload indicators
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2013-12-04
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Intraoperative optimization of cardiac output using goal directed fluid challenge is associated with better outcome. Dynamic preload dependence indicators are well validated during surgery in supine position. Positioning from supine to sitting position under anesthesia is responsible of several hemodynamic changes. Predictability and cut-off values of dynamic preload dependence indicators during surgery in sitting position are unknown. The objective of this prospective study is to evaluate ability of three dynamic preload dependence indicators, i.e. PPV (Pulse Pressure Variation), SVV (Stroke Volume Variation) and PVI (Plethysmographic Variability Index), during neurosurgery in sitting position.

Detailed description: The primary objective is to determine PPV, SVV and PVI thresholds for which patients respond to fluid challenge in sitting position.

The secondary objectives are to determine variations of PPV, SVV and PVI measures before and after positioning in sitting position, and to compare these values to each other.

Eligibility criteria: Inclusion Criteria:

* neurosurgery in sitting position
* age \> 18

Exclusion Criteria:

* arrhythmias
* severe heart failure
* severe lung disease
* contraindications to esophageal Doppler monitoring probe insertion (i.e. esophageal weakness)
* renal failure

Primary outcomes:
measure: PPV (Pulse pressure variation)
timeFrame: 3 minutes before and after fluid challenge in sitting position
measure: SVV (Stroke volume variation)
timeFrame: 3 minutes before and after positioning in sitting position
measure: PVI (Plethysmographic variability index)
timeFrame: 3 minutes before and after positioning in sitting position
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Fédération d'anesthésie réanimation Hôpital Pierre Wertheimer
Study officials:
References:
Clinical trial NCT02328170: Comparative Study of Specific IgE Levels to Common Foods and Aeroallergens Measured by EUROIMMUN Allergy and ImmunoCap
Official title: Comparative Study of Specific IgE Levels to Common Foods and Aeroallergens Among Thai Children Measured by EUROIMMUN Allergy and ImmunoCap
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Allergy
Keywords: immunoglobulin E, food hypersensitivities, child, allergens
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2014-12-31
Enrollment: 235
Sex: ALL
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who was diagnosed as having asthma and/or allergic rhinitis and/or atopic dermatitis and/or food allergy, were enrolled.

Brief summary: The purpose of this study is to determine the correlation of specific IgE levels to common foods and aeroallergens measured by EUROIMMUN Allergy and ImmunoCap

Detailed description: Children aged 0-15 years old who was diagnosed as asthma and/or allergic rhinitis, atopic dermatitis, food allergy, and underwent to measured specific IgE levels to suspicious relevant allergen, were invited to join the study.

Specific IgE levels of each patient was measured by EUROIMMUN Allergy and ImmunoCap.

The levels of specific IgE to Dermatophagoides pteronyssinus, Dermatophagoides farinae, American cockroach, Bermuda, Johnson, Cat dander, Cow's milk, Egg white and wheat were determined the correlation between these two methods.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosed as asthma and/or allergic rhinitis and/or atopic dermatitis and/or food allergy and have to measured specific IgE levels to relevant allergens

Exclusion Criteria:

* Having underlying disease including cardiovascular disease, chronic lung disease and immunodeficiency disease
* Denied to enrolled to the study

Primary outcomes:
measure: specific IgE levels measured by EUROIMMUN Allergy and ImmunoCap
timeFrame: 14 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University
Study officials:
affiliation: Mahidol University
name: Jittima Veskitkul, Assist Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06012370: Injecting Plasma-rich Platelets & Hyaluronic Acid for Patients With Stress Urinary Incontinence
Official title: A Pilot Study of Injecting Plasma-rich Platelets and Hyaluronic Acid for Patients With Stress INCONTINENCE; A NON-RANDOMIZED CLINICAL TRIAL
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Stress Incontinence, Female
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2023-08-25
Enrollment: 20
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Injection of PRP and hyaluronic acid in stress incontinence patients

Detailed description: Operative details Dissection of the ant vag wall from the urethra and lower part of the bladder Identify the bladder neck using Foly s catheter injection of 1.5 to 2 ml PRP combined with Hyaluronic acid suburethra almost at the level of mid urethra (avoiding the bl neck) then closure of the vag wall ( after removal of the excess vag tissue.

Eligibility criteria: Inclusion Criteria:

* stress incontinence patients

Exclusion Criteria:

* prolapse patients

Primary outcomes:
measure: Stress incontinence change
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00488670: Escitalopram and Depression in Elderly Alzheimer's Patients
Official title: An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Depressive Disorder
Keywords: Alzheimer's disease
elderly
open-label
escitalopram
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2007-06-20
Enrollment: 50
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Detailed description: This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Eligibility criteria: Inclusion Criteria:

* \> 50 years
* Male \& female
* Alzheimer's disease
* Depressive episode

Primary outcomes:
measure: Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
Secondary outcomes:
measure: Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Mt. St. Joseph's Hospital
state: British Columbia
city: Vancouver
country: Canada
facility: Vancouver General Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Kiran Rabheru, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06403670: Dexmedetomidine and Remifentanil in NORA
Official title: The Effects of Dexmedetomidine and Remifentanil on Sedation and Comfort in Non-Operating Room Anesthesia: A Randomized, Double-blind, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Comparison of the Effects of Remifentanil and Dexmedetomidine
Lead sponsor: Baskent University Ankara Hospital
Sponsor class: OTHER
First posted: 2024-05-08
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Endoscopic retrograde cholangiopancreatography (ERCP) procedure is frequently encountered in non-operating room anesthesia applications (NORA). It is a procedure that requires deep sedation and analgesia in terms of gastroenterologist and patient comfort. Dexmedetomidine, which is increasingly used in NORA applications, comes to the fore because it does not cause respiratory depression, reduces the stress response, and provides hemodynamic stability. This study aims to compare the effects of dexmedetomidine-propofol (DP) and remifentanil-propofol (RP) combinations on hemodynamic stability, rapid recovery, and patient comfort in patients who underwent ERCP.


Eligibility criteria: Inclusion Criteria:

-ASA 1-3

Exclusion Criteria:

* Neurological disease,
* Psychiatric disease,
* Coronary artery disease,
* Long-term sedative drug use,
* Pregnant patients,
* Known allergy to planned drugs

Primary outcomes:
measure: Agitation-Sedation
timeFrame: 0 and 5 minutes after ERCP ends
measure: Hemodynamic stability
timeFrame: 5, 10, 15, 25, 35. minutes
Secondary outcomes:
measure: Minimize drug dose
timeFrame: 5, 10, 15, 25, 35. minutes
measure: Patient comfort
timeFrame: 30 minutes after ERCP ends
measure: Rapid recovery
timeFrame: 30 minutes after ERCP ends
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Baskent University Ankara Hospital
state: Cankaya
Study officials:
References:
Clinical trial NCT06690970: Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Official title: Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: PSMA-related Disease
Prostate Cancer
Positron Emission Tomography
Metastasis
FAP
Keywords: PET/CT
PSMA
FAP
Lead sponsor: Tianjin Medical University
Sponsor class: OTHER
Collaborators: name: Tianjin Medical University General Hospital
First posted: 2024-11-15
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Brief summary: To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.

Detailed description: Subjects with various PSMA-related disease patients underwent 68Ga/18F-PSMA/PSFA PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-PSMA/PSFA PET/CT were calculated.

Eligibility criteria: Inclusion Criteria:

- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Primary outcomes:
measure: Standardized uptake value (SUV)
timeFrame: 30 days
Secondary outcomes:
measure: Diagnostic efficacy
timeFrame: 30 days
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
state: Tianjin
Study officials:
References:
Clinical trial NCT04561570: Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control
Official title: Long Term Outcomes of Vivity IOL Versus Control
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cataract
Lead sponsor: Vance Thompson Vision
Sponsor class: OTHER
Collaborators: name: Alcon Research
name: The Eye Associates
name: Eye Care Specialists
name: NewsomeEye
First posted: 2020-09-23
Enrollment: 32
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 45-60 subjects will be enrolled (30-45 subjects that received the Vivity IOL and 15-20 subjects that received the control lens in the FDA clinical trial) across up to five investigational sites.

Brief summary: Evaluate the long-term (\>1 yr) outcomes of the Vivity IOL. The investigator will use similar measurements and procedures to the ones performed on these subjects during the FDA clinical trial.


Eligibility criteria: Inclusion Criteria:

Must have participated in the FDA study at one of the included sites

Exclusion Criteria:

None

Primary outcomes:
measure: Best Corrected Distance Visual Acuity (BCDVAA)
timeFrame: After 1 year post-op
measure: Best Corrected Intermediate Visual Acuity (BCIVA)
timeFrame: After 1 year post-op
measure: Defocus Curve
timeFrame: After 1 year post-op
Secondary outcomes:
measure: Uncorrected Distance Visual Acuity (UCDVA)
timeFrame: After 1 year post-op
measure: UCNVA
timeFrame: After 1 year post-op
measure: Dyphotopsia rate
timeFrame: After 1 year post-op
measure: Post-operative IOLSAT
timeFrame: After 1 year post-op
measure: (Post-operative QUVID)
timeFrame: After 1 year post-op
Other outcomes:
Locations:
city: Sioux Falls
country: United States
facility: Vance Thompson Vision
state: South Dakota
Study officials:
References:
Clinical trial NCT02317770: Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy
Official title: Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Anesthesia of Mucous Membrane
Keywords: lidocaine, esophago-gastro-duodenoscopy
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2014-12-16
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the effect of nebulized lidocaine and lidocaine spray in patients undergoing esophago-gastro-duodenoscopy. The investigators evaluate the success rate of the procedure between two methods.

Detailed description: This is a randomized-controlled trial in the patients undergoing esophago-gastro-duodenoscopy. The patients are randomized by computer into two arms: nebulized lidocaine and lidocaine spray. Both drugs are applied 15-20 minutes prior the prior the procedure. Only one endoscopist participate in this study. After the procedure finishes, the investigators evaluate the outcome and satisfaction of patients and endoscopist.

Eligibility criteria: Inclusion Criteria:

* elective case for esophago-gastro-duodenoscopy with ASA classification 1-2
* Both genders
* Age between 18-65 years

Exclusion Criteria:

* History of smoking
* Upper respiratory tract infection
* Asthma
* Heart disease
* Allergy to local anesthetic drugs

Withdrawal or termination criteria

* Patient refusal
* Patient develops lidocaine allergy
* Bronchospasm
* Sign of Local Anesthetic Toxicity

Primary outcomes:
measure: Comparison of Topical and Nebulized Anesthesia
timeFrame: 90 min
Secondary outcomes:
measure: Patient Satisfaction
timeFrame: 90 min
measure: Operator Satisfaction
timeFrame: 30 min
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Faculty of Medicine Siriraj Hospital
state: Bangkok
Study officials:
affiliation: Department of Anesthesia, Faculty of Medicine Siriraj Hospital
name: Papiroon Noitasaeng, RN
role: PRINCIPAL_INVESTIGATOR
References:
citation: Korttila K, Tarkkanen J, Tarkkanen L. Comparison of laryngotracheal and ultrasonic nebulizer administration of lidocaine in local anaesthesia for bronchoscopy. Acta Anaesthesiol Scand. 1981 Apr;25(2):161-5. doi: 10.1111/j.1399-6576.1981.tb01628.x.
citation: Dhir V, Swaroop VS, Vazifdar KF, Wagle SD. Topical pharyngeal anesthesia without intravenous sedation during upper gastrointestinal endoscopy. Indian J Gastroenterol. 1997 Jan;16(1):10-1.
Clinical trial NCT02372370: Pretreatments of the Skin Prior to PDT
Official title: Pretreatments of the Skin to Enhance MAL-induced Protoporphyrin IX (PpIX) Accumulation Prior to Photodynamic Therapy (PDT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2015-02-26
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study investigates the potential of a range of different physical pretreatments to enhance methyl aminolevulinate (MAL)-induced protoporphyrin IX (PpIX) in the skin prior to photodynamic therapy (PDT).

Detailed description: The study investigates the potential of a range of different physical pretreatments to enhance methyl aminolevulinate (MAL)-induced protoporphyrin IX (PpIX) in the skin prior to photodynamic therapy (PDT). The pretreatments include: microneedling, sandpaper, curettage, ablative fractional laser and non-ablative fractional laser. 17 treatment areas are mapped on the upper back of the participants. Each participant receives each intervention in a random sequence.

Primary outcome measure: PpIX accumulation after 3 hours incubation with MAL. Secondary outcome measures: pain during treatment and skin reactions.

Eligibility criteria: Inclusion Criteria:

* 18 years or older, healthy, fair skinned (skin type I-III)

Exclusion Criteria:

* Pregnant women
* Tattoos, moles or scars in treatment area

Primary outcomes:
measure: Protoporphyrin IX (PpIX) fluorescence
timeFrame: Day 0
Secondary outcomes:
measure: Pain
timeFrame: Day 0
measure: Skin reactions
timeFrame: Day 0, Day 1, Day 3, Day 7
Other outcomes:
Locations:
Study officials:
References:
citation: Bay C, Lerche CM, Ferrick B, Philipsen PA, Togsverd-Bo K, Haedersdal M. Comparison of Physical Pretreatment Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: A Randomized Clinical Trial. JAMA Dermatol. 2017 Apr 1;153(4):270-278. doi: 10.1001/jamadermatol.2016.5268.
Clinical trial NCT01896570: Role of Subsequent Atrial Tachycardia in Mechanisms of Persistent AF
Official title: The Prognostic Role of Subsequent Atrial Tachycardias Occurring After Atrial Fibrillation Termination: A Prospective Randomized Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: atrial fibrillation
catheter ablation
subsequent atrial tachycardia
mechanisms
Lead sponsor: Johannes Gutenberg University Mainz
Sponsor class: OTHER
First posted: 2013-07-11
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with persistent AF

Brief summary: In this study, the investigators aim to examine the prognostic role of subsequent Atrial Tachycardias (ATs) in the mechanisms of atrial fibrillation (AF). Therefore, the investigators compare patients who were randomly assigned to either undergo cardioversion after AF has been terminated to AT or further ablation until the achievement of sinus rhythm.


Eligibility criteria: Inclusion Criteria:

* persistent AF for at least 1 months,
* age \> 18 years,
* refractory to drug therapy,
* no prior ablation

Exclusion Criteria:

* prior AF ablation

Primary outcomes:
measure: Arrhythmia-free survival
timeFrame: 24 months after enrolment
Secondary outcomes:
measure: Type of Arrhythmia recurrence
timeFrame: 24 months after enrolement
Other outcomes:
measure: Time to recurrence
timeFrame: after blanking period (3 months) until study end (at least 24 months)
Locations:
city: Hamburg
country: Germany
facility: University Hospital Eppendorf, Dept. of Electrophysiology
Study officials:
References:
citation: Rostock T, Salukhe TV, Hoffmann BA, Steven D, Berner I, Mullerleile K, Theis C, Bock K, Servatius H, Sultan A, Willems S. Prognostic role of subsequent atrial tachycardias occurring during ablation of persistent atrial fibrillation: a prospective randomized trial. Circ Arrhythm Electrophysiol. 2013 Dec;6(6):1059-65. doi: 10.1161/CIRCEP.113.001019. Epub 2013 Oct 25.
Clinical trial NCT01843270: Appropriate Laryngeal Mask Airway Size in Patients With Overweight: A Comparison of the Actual Body Weight and Ideal Body Weight
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: General Anesthesia
Keywords: general anesthesia
body weight
laryngeal mask airway size
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-04-30
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The classic laryngeal mask airway is one of the keystones of modern anaesthetic practice. It achieves a reliable airway with a low incidence of major complications and pharynges-laryngeal morbidity. The manufactures of laryngeal mask airway recommend the proper size selection by actual body weight. It was recommended a size 3 for 30-70kg, a size 4 for 70-90 kg, and size 5 for \> 90 kg. Obesity increases the fat tissue around an upper airway and decreases the pharyngeal cross sectional area. Also it was reported that pharyngeal area was reduced according to the increasing of BMI. Therefore, the aim of this study is to determine which of actual body weight or ideal body weight is proper on the size selection of laryngeal mask airway.


Eligibility criteria: Inclusion Criteria:

* age 20\~70
* body mass index \> 25 kg/m2
* patient who needs surgery with laryngeal mask airway

Exclusion Criteria:

* difficult airway
* upper airway infection or disease of airway
* history of gastroesophageal reflux
* history of head and neck surgery

Primary outcomes:
measure: Oropharyngeal leak pressure
timeFrame: 10mins
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
citation: Kim MS, Lee JS, Nam SB, Kang HJ, Kim JE. Randomized Comparison of Actual and Ideal Body Weight for Size Selection of the Laryngeal Mask Airway Classic in Overweight Patients. J Korean Med Sci. 2015 Aug;30(8):1197-202. doi: 10.3346/jkms.2015.30.8.1197. Epub 2015 Jul 15.